Lee Enterprises Reports Fourth Quarter and Full-Year FY24 results
December 12, 2024 07:00 ET
|
Lee Enterprises Inc.
Total Digital Revenue(1) was 51% of revenue in the quarter, representing $82MDigital-only subscription revenue increased 30%(2) in the quarterAmplified Digital® Agency revenue totaled $28M in the...
Liquidity Services Announces Fourth Quarter Fiscal Year 2024 Financial Results
December 12, 2024 06:55 ET
|
Liquidity Services, Inc.
BETHESDA, Md., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Liquidity Services (NASDAQ:LQDT; www.liquidityservices.com), a leading global commerce company powering the circular economy, today announced its...
Niu Technologies Announces Unaudited Third Quarter 2024 Financial Results
November 18, 2024 03:00 ET
|
NIU Technologies
-- Third Quarter Revenues of RMB 1,023.9 million, an increase of 10.5% year-over-year -- Third Quarter Net Loss of RMB 40.9 million, compared to Net Loss of RMB 79.4 million in the same period of...
Beneficient Reports Results for Second Quarter Fiscal 2025
November 14, 2024 16:45 ET
|
Beneficient
Beneficient today reported its financial results for the fiscal 2025 second quarter, which ended September 30, 2024.
Agrify Corporation Announces Results for Third Quarter 2024
November 14, 2024 16:03 ET
|
Agrify
Agrify Corporation Announces Results for Third Quarter 2024
Stryve Foods, Inc. Reports Fiscal 2024 Third Quarter Results
November 13, 2024 16:15 ET
|
Stryve Foods, Inc.
Stryve Foods, Inc. (Nasdaq: SNAX) Reports Fiscal 2024 Third Quarter Results
First Advantage Reports Third Quarter 2024 Results
November 12, 2024 06:30 ET
|
First Advantage Corporation
Third Quarter 2024 Highlights1 Revenues of $199.1 millionNet Loss of $(8.9) million, a net loss margin of (4.4)%, includes $13.2 million of expenses incurred related to the acquisition of Sterling...
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
November 08, 2024 08:00 ET
|
Monopar Therapeutics Inc.
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid...
HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
November 07, 2024 08:00 ET
|
HilleVax, Inc.
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
Aveanna Healthcare Holdings Announces Third Quarter 2024 Financial Results and Revised 2024 Outlook
November 07, 2024 06:30 ET
|
Aveanna Healthcare Holdings, Inc
Third Quarter Revenue was $509.0 million, a 6.5% increase over the prior year period Gross margin increased 8.4% to $159.7 million, compared to Q3 2023 Third Quarter Net loss was $42.8 million,...